Our cells rely on microscopic highways and specialized protein vehicles to move everything—from positioning organelles to carting protein instructions to disposing of cellular garbage. These highways ...

Lower motor neuron (LMN) syndromes are clinically characterised by muscle atrophy, weakness and hyporeflexia without sensory involvement. They may arise from disease processes affecting the anterior ...

Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet. This is ...

The results of the MIROCALS randomised clinical trial showed that adding low-dose interleukin-2 (IL2LD) to standard treatment ...

A clinical trial has found that low-dose interleukin-2 is safe and may significantly extend survival in people with motor ...

A clinical trial has found that low-dose interleukin-2 is both safe and effective for use on people with motor neuron disease ...

Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet.

Results of the landmark MIROCALS clinical trial, published in The Lancet, show a low-dose interleukin-2 (IL2LD) is safe, ...

Results of the landmark MIROCALS clinical trial, involving researchers from the University of Sheffield, have revealed new ...

BioRestorative Therapies is a regenerative medicine company that wants to alleviate chronic lower back pain, obesity and diabetes and is developing stem cell therapies to meet that end.

Alex Gibson, left, walked the final 356 metres of the London marathon on Sunday (Challenging MND/PA) A man with motor neurone disease (MND) walked the final 356 metres of the London marathon in an ...

A man with motor neurone disease (MND) walked the final 356 metres of the London marathon in an act of “courage” and “bravery”. After being diagnosed in 2018, Alex Gibson, 47, founded the ...